

Claims

1. Use of an immunogen specific for a pathogenic agent having a gateway in a mucous membrane for the production of an immunogenic composition intended to be administered to man by the parenteral route at the surface of a part of the body distinct and distant from said mucous membrane, so as to directly develop a local response in respect of IgA, IgG and/or IgM antibodies and of B cells which secrete said antibodies in said mucous membrane and the lymph nodes which drain it.
2. Use according to Claim 1, characterized in that the mucous membrane is composed of the rectal, genital and/or urinary mucous membranes and that the administration by the parenteral route is carried out in the thigh.
3. Use according to Claim 1, characterized in that secretory IgAs are developed.
4. Use according to Claim 1, characterized in that a response in respect of B cells which secrete IgG, IgM and/or IgA respectively in the rectal, genital and/or urinary mucous membranes and the lymph nodes which drain them is developed.
5. Use according to Claim 2, characterized in that the immunogenic composition is intended to be administered by the intramuscular route in the thigh.
6. Use according to Claim 5, characterized in that the immunogenic composition is intended to be administered in the quadriceps(es), in particular the right anterior muscle(s).

F03360"CT502260

7. Use according to one of Claims 1 to 5, characterized in that the immunogenic composition is intended also to develop a systemic response.
- 5
8. Use according to any one of Claims 1 to 5, characterized in that the immunogenic composition is directed against a pathogen chosen from the group consisting of: the HIV virus, Herpes viruses, in particular Herpes simplex, Candida species, Chlamydia species, the human papillomavirus, genital mycoplasmas, Treponema pallidum and gonococcal infections.
- 10
- 15 9. Use according to one of Claims 1 to 8, in combination with the use of another immunogenic composition, identical to or different from the preceding one, intended to be administered in the oral cavity to the same subject so as to additionally induce a response in respect of IgG and/or IgA antibodies and also of B cells which secrete IgG and/or IgA in the buccal mucous membrane and the lymph nodes which drain it.
- 20

09720543 032604
FOIA b7E b7D

all a'